Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-227-2 | CAS number: 1314-23-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Acute/short term exposure
DNEL related information
Local effects
Acute/short term exposure
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Acute/short term exposure
DNEL related information
Workers - Hazard for the eyes
Additional information - workers
Acute / short-term exposure - systemic and local effects
Inhalation:
As no local or systemic effects have been observed in the available toxicological studies up to the maximal technically achievable concentration, no DNEL needs to be derived.
Dermal:
No acute toxicity study for the dermal route is available for zirconium dioxide, however, this study can be waived based on Column 2 adaptation (REACH Regulation, Annex VIII, section 8.5) (acute toxicity data via two routes available). As there are no acute toxicity data available via dermal route for zirconium dioxide, no acute/short-term DNEL could be derived. In addition, the dermal route is not the most appropriate route as exposure via inhalation is more likely and there is no indication from the physicochemical and toxicological properties of significant absorption through the skin (Annex VIII, 8.5.3, Column 2 adaptation).
Long-term exposure - systemic and local effects
Inhalation:
The study from Spiegl et al. (1956) provides a NOAEL for zirconium dioxide >= 15.4 mg/m3 after 60 days of exposure and >= 100.8 mg/m3 after 30 days, nevertheless only one dose was tested in these studies. It can be concluded from this study that the NOAEC will be higher than (or equal to) these doses tested. It is not recommended to derive a DNEL value based on these unbound NOAECs, because the DNEL will be unrealistically low and not representative for zirconium dioxide. Zirconium dioxide was shown to be a compound with extremely low potential for causing toxicity. Indeed, in none of the available studies, zirconium dioxide causes adverse health effects (acute/long-term, oral/inhalation). This is mainly driven by the fact that this substance has a very low water solubility (< 55 µg/L) and thus a very low bioavailability as demonstrated in the toxicokinetics assessment.
National exposure limits for zirconium compounds were defined in Europe by 15 national authorities and set at 5 mg/m3 (expressed as Zr). In the USA, NIOSH, ACGIH, and OSHA have evaluated toxicity and defined long-term and short-term exposure limits for zirconium dioxide. The 8-h Time Weighted Average (TWA) was set at 5 mg Zr/m3 whereas the Short Term Exposure Limit (STEL) was set at 10 mg Zr/m3. These values were based on the results of Spiegl et al. (1956) as well as on the results of the study from Hodge (1955). The study of Hodge (1955), is a 1-year experiment performed on rats with zirconium oxide dust at a a low dose of 3.5 mg/m3.Unfortunately the unpublished study was not accessible. As zirconium dioxide did not show any toxic effects in the available studies, it is considered reasonable not to derive DNELs, however, the national exposure limits as mentioned above should be respected where relevant.
Dermal:
No reliable studies are available for repeated dose toxicity via the dermal route of exposure. Testing is waived based on the following justification: a short-term (30 days) and sub-chronic (60 days) study are available for the inhalation route of exposure and, according to the REACH Regulation, only one route of exposure should be tested for repeated dose toxicity (Column 2 adaptation, annex VIII, section 8.6.1). Therefore, it was not necessary to perform a repeated dose toxicity study via the dermal route of exposure.
There are no long-term dermal toxicity data available for zirconium dioxide, hence no long-term DNEL could be derived.
In addition, the dermal route is not the most appropriate route as exposure via inhalation is more likely and there is no indication from the physicochemical and toxicological properties of significant absorption through the skin (Annex VIII, 8.5.3, column 2 adaptation).
For inhalation, no long-term systemic DNEL was derived based on the above argumentation. Therefore, no dermal long-term systemic DNEL should be derived by extrapolation from inhalation studies. No extrapolation from the available oral repeated dose toxicity studies (performed with the read across substances zirconium acetate and zirconium basic carbonate) should be performed either because no adverse effects were observed in these studies up to the highest (limit) test doses.
Hazards for the eyes
Based on read across from a study with yttrium zirconium oxide, zirconium dioxide was concluded not to be classified as hazardous to eyes.
General Population - Hazard via inhalation route
Systemic effects
Acute/short term exposure
DNEL related information
Local effects
Acute/short term exposure
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Acute/short term exposure
DNEL related information
General Population - Hazard via oral route
Systemic effects
Acute/short term exposure
DNEL related information
General Population - Hazard for the eyes
Additional information - General Population
Acute / short-term exposure - systemic and local effects
Inhalation:
As no local or systemic effects have been observed in the available toxicological studies up to the maximal technically achievable concentration, no DNEL needs to be derived.
Dermal:
There are no acute dermal toxicity data available for zirconium dioxide, hence no acute/short-term DNEL could be derived. There is no indication from the physicochemical and toxicological properties of significant absorption through the skin (Annex VIII, 8.5.3, column 2 adaptation). Furthermore, no indication of potential dermal toxicity is assumed from the available data.
Oral:
Based on available experimental data, there are no acute toxic effects leading to classification and labeling, hence no acute/short-term DNEL needs to be derived.
Long-term exposure - systemic and local effects
Inhalation:
Based on the available data and the same argumentation as for workers, no long-term DNEL needs to be derived for the general population. In addition, no officially set values are available for the general population.
Dermal route:
Based on the same argumentation as for workers (no long-term dermal toxicity data available, no adverse effects observed in oral and inhalation repeated dose toxicity studies), no long-term DNEL needs to be derived for the general population.
Oral:
No oral repeated dose toxicity studies are available for zirconium dioxide, however, read across can be performed from two studies with zirconium basic carbonate (another insoluble zirconium compound) and zirconium acetate (a 'water soluble' zirconium compound). In these studies, no adverse effects were observed up to the highest (limit) test dose. Therefore, it is not considered necessary to derive a long-term DNEL.
Further argumentation on read across and the overall extremely low potential of zirconium compounds for causing toxicity is given in the read across justification attached to Section 13 of IUCLID.
Hazards for the eyes
Based on read across from a study with yttrium zirconium oxide, zirconium dioxide was concluded not to be classified as hazardous to eyes.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.